This site is intended for US patients and caregivers.

How FOTIVDA was studied

The effectiveness and safety of FOTIVDA was proven in a large clinical study of people (350 people in total) with relapsed or refractory advanced kidney cancer where at least 2 medicines stopped working. These medicines included an immunotherapy and other treatments, including vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs). During the study, 175 people with advanced RCC were randomly chosen to take FOTIVDA and 175 were chosen to take sorafenib.

The results:

44% increase in time without tumor growth or spread (5.6 months for FOTIVDA vs 
3.9 months for sorafenib)
28% (49/175) experienced no cancer growth or spread for 1 year (compared with 11% [19/175] taking sorafenib)

FOTIVDA showed tumor control

Twice as many people who took FOTIVDA had their tumor(s) get smaller in size

18% (32/175) 
experienced tumor shrinkage (compared with 8% [14/175] taking sorafenib)

More people who took FOTIVDA had disease control

73% (128/172) 
experienced disease control (compared with 65% [114/175] taking sorafenib)

Learn more about some possible side effects of FOTIVDA.

See the Safety Results

FOTIVDA® (tivozanib) is a prescription medicine used to treat adults with advanced kidney cancer (advanced renal cell carcinoma or RCC) that has been treated with 2 or more prior medicines and has come back or did not respond to treatment.

IMPORTANT SAFETY INFORMATION

Possible serious side effects can occur with FOTIVDA. Call or see your healthcare provider right away if you develop:

High blood pressure (hypertension). High blood pressure may be severe, including a sudden, severe increase in your blood pressure (hypertensive crisis) that can

FOTIVDA® (tivozanib) is a prescription medicine used to treat adults with advanced kidney cancer (advanced renal cell carcinoma or RCC) that has been treated with 2 or more prior medicines and has come back or did not respond to treatment.

IMPORTANT SAFETY INFORMATION

Possible serious side effects can occur with FOTIVDA. Call or see your healthcare provider right away if you develop:

High blood pressure (hypertension). High blood pressure may be severe, including a sudden, severe increase in your blood pressure (hypertensive crisis) that can lead to death. Your healthcare provider should check your blood pressure after 2 weeks and at least monthly, and may prescribe medicine to treat high blood pressure. You should check your blood pressure regularly and tell your healthcare provider if you have increased blood pressure or experience confusion, headaches, dizziness, chest pain, or shortness of breath.

Heart failure. Heart failure may be serious and sometimes lead to death. Your healthcare provider should check for symptoms of heart failure regularly, such as shortness of breath or swelling of your ankles.

Heart attack and blood clots in your veins or arteries. Blood clots may be serious and sometimes lead to death. Tell your healthcare provider or get emergency medical help right away if you have:

  • new chest pain or pressure
  • numbness or weakness on one side of your body
  • pain in your arms, back, neck or jaw
  • trouble talking
  • shortness of breath
  • sudden severe headache
  • vision changes
  • swelling in the arms or legs

Bleeding problems. Bleeding may be serious and sometimes lead to death. Report or get medical help right away if you have:

  • unusual bleeding from the gums
  • red or black stools (looks like tar)
  • menstrual bleeding or vaginal bleeding that is heavier than normal
  • bruises that happen without a known cause or get larger
  • headaches, feeling dizzy or weak
  • bleeding that is severe or you cannot control
  • coughing up blood or blood clots
  • pink or brown urine
  • vomiting blood or your vomit looks like “coffee grounds”
  • unexpected pain, swelling, or joint pain

Protein in your urine. Your healthcare provider should check your urine for protein before and during treatment.

Thyroid gland problems. Your healthcare provider should do blood tests to check your thyroid gland function before and during your treatment, and may prescribe medicine if you develop thyroid gland problems.

Risk of wound-healing problems. Wounds may not heal properly during treatment. Tell your healthcare provider if you plan to have surgery before starting or during treatment, including dental surgery.

  • You should stop taking FOTIVDA at least 24 days before planned surgery.
  • Your healthcare provider should tell you when you may start taking FOTIVDA again after surgery.

Reversible Posterior Leukoencephalopathy Syndrome (RPLS). RPLS is a condition that can happen. Tell your healthcare provider right away if you have headaches, seizures, confusion, blindness or changes in vision, or difficulty thinking.

Allergic reactions to tartrazine (FD&C Yellow No. 5). FOTIVDA contains a dye called FD&C Yellow No. 5 (tartrazine) that may cause allergic-type reactions, including bronchial asthma, in certain people. This occurs most often in people who also are allergic to aspirin.

The most common side effects of FOTIVDA include:

  • tiredness
  • diarrhea
  • decreased appetite
  • nausea
  • hoarseness
  • low levels of thyroid hormones
  • cough
  • mouth sores
  • decreased blood levels of salt (sodium) and phosphate
  • increased levels of lipase in the blood

Other side effects include vomiting and weakness or lack of energy. FOTIVDA may cause fertility problems in males and females, which may affect your ability to have a child.

Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with FOTIVDA if you have certain side effects.

These are not all of the possible side effects of FOTIVDA.

Before taking FOTIVDA, tell your healthcare provider about all your medical conditions, including if you:

  • have high blood pressure.
  • have a history of heart failure.
  • have a history of blood clots in your veins or arteries (types of blood vessels), including stroke, heart attack, or change in vision.
  • have bleeding problems.
  • have thyroid problems.
  • have liver problems.
  • have an unhealed wound.
  • plan to have surgery or have had recent surgery, including dental surgery. You should stop taking FOTIVDA at least 24 days before planned surgery.
  • are allergic to FD&C Yellow No.5 (tartrazine) or aspirin.
  • are pregnant or plan to become pregnant. FOTIVDA can harm your unborn baby. If you are able to become pregnant:
    • Your healthcare provider should do a pregnancy test before you start treatment.
    • Use effective birth control (contraception) during treatment and for 1 month after your last dose.
    • Talk to your healthcare provider about birth control methods that may be right for you.
    • Tell your healthcare provider right away if you become pregnant or think you might be pregnant.

Tell your healthcare provider about all the medicine you take and any new medicine, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking FOTIVDA with certain other medicines may affect how FOTIVDA works.

To report SUSPECTED ADVERSE REACTIONS, contact AVEO Pharmaceuticals, Inc. at 1-833-FOTIVDA (1-833-368-4832) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the Patient Information in the full Prescribing Information for FOTIVDA® (tivozanib).